Thus, combined treatment may be an optimal therapeutic solution for retinal vein occlusion-related ME to reduce the injection frequency of anti-VEGF agents and the risk of cataract or ocular hypertension caused by Ozurdex implant [43]. This evidence concerns the gene VEGFA and ocular hypertension.